A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Eli Lilly and Company
Canadian Cancer Trials Group
AbbVie
City of Hope Medical Center
NYU Langone Health